Industry News

AbbVie announced financial results for the second quarter ended June 30, 2016.. "AbbVie continues to deliver on our long-term strategy, as demonstrated by our sixth consecutive quarter of double digit sales and earnings growth," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "A key element to our long-term sustainable performance is our advancing pipeline and this quarter we saw several regulatory approvals,..."/>
AbbVie Reports Second-Quarter 2016 Financial Results
Sunesis Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2016. Loss from operations for the three months ended June 30, 2016 was $10.0 million. As of June 30, 2016, cash, cash equivalents and marketable securities totaled $33.1 million."/>
Sunesis Pharmaceuticals Reports Second Quarter 2016 Financial Results and Recent Highlights
IRADIMED CORPORATION, the only known provider of non-magnetic intravenous infusion pump systems that are designed to be safe for use during magnetic resonance imaging..."/>
IRADIMED CORPORATION Announces Second Quarter 2016 Financial Results
Seres Therapeutics, Inc., a leading microbiome therapeutics company, today announced interim 8- week results from the ongoing SER-109 Phase 2 ECOSPOR TM clinical study for the prevention of multiply recurrent Clostridium difficile infection."/>
Seres Therapeutics Announces Interim Results from SER-109 Phase 2 ECOSPOR Study in Multiply Recurrent Clostridium difficile Infection
Shire plc today announced that the United States Food and Drug Administration has granted Fast Track designation for SHP626 for an investigational treatment of adults who have nonalcoholic steatohepatitis with liver fibrosis. Shire is developing SHP626 as a once daily, orally-administered inhibitor of the apical sodium dependent bile acid transporter, a protein which is primarily responsible for recycling bile acids..."/>
Shire's SHP626 (Volixibat) Receives FDA Fast Track Designation for an Investigational Treatment for Adults Who Have Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis
Ventas, Inc. today announced strong earnings on a healthy balance sheet for the second quarter of 2016, driven by excellent performance from the Company’ s high-quality healthcare and senior living properties and accretive acquisitions:."/>
Ventas Reports 2016 Second Quarter Results
Caladrius Biosciences, Inc., a cell therapy company combining an industry-leading development and manufacturing services provider, PCT, with a select therapeutic development pipeline, announces today that its product candidate CLBS03 was granted Fast Track designation by the US Food and Drug Administration for the treatment of type 1 diabetes mellitus, making it the first known therapeutic candidate for treatment of T1D to receive the designation."/>
Caladrius Biosciences Receives FDA Fast Track Designation for CLBS03 to Treat Recent Onset Type 1 Diabetes
Merck Announces Second-Quarter 2016 Financial Results
Acadia Healthcare Company, Inc. today announced financial results for the second quarter and six months ended June 30, 2016."/>
Acadia Healthcare Reports Second Quarter GAAP EPS of $0.65 and Adjusted EPS of $0.73, up 28.1%
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced that Paul Edick will join Sucampo's Board of Directors on August 1. Edick is the former CEO of Durata Therapeutics and currently the founding partner of 3 G Advisors. "I am pleased to welcome Paul to Sucampo’ s Board of Directors," said Peter Greenleaf, Chairman and Chief Executive Officer of Sucampo.“ Paul is a well-rounded and seasoned chief executive with a depth of..."/>
Paul Edick Joins Sucampo’s Board of Directors
Edge Therapeutics, Inc., a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today announced that the first patient has been treated in NEWTON 2, a Phase 3, multi-center, multi-national, randomized, double-blind, placebo-controlled,..."/>
Edge Therapeutics Announces First Patient Treated in Phase 3 NEWTON 2 Study of EG-1962 in Adult Patients with Aneurysmal Subarachnoid Hemorrhage
Magellan Health, Inc. today reported financial results for the second quarter of 2016, as summarized below. For the quarter ended June 30, 2016, the company reported net revenue of $1.16 billion, segment profit of $56.9 million, and net income of $4.0 million, or $0.16 per diluted common share. In addition, the company reported adjusted net income of $14.4 million and adjusted earnings per share of $0.58."/>
Magellan Health Reports Second Quarter 2016 Financial Results
InfuSystem Holdings, Inc., a leading national provider of infusion pumps and related services for the healthcare industry in the United States and Canada, today announced that its chief financial officer, Jonathan P. Foster, has resigned effective August 11, 2016 to pursue a similar role with another public company. Effective August 11, 2016, the Company will appoint Christopher Downs, CTP, FP&A, its current vice president&..."/>
InfuSystem Holdings, Inc. Announces Resignation Of Chief Financial Officer And Replacements
LifePoint Health, Inc. today announced results for the second quarter and six months ended June 30, 2016.. For the second quarter ended June 30, 2016, consolidated revenues were $1,592.4 million, up 25.3% from $1,270.4 million for the same period last year, primarily as a result of our recent acquisitions in Flemingsburg, Kentucky, Jeffersonville, Indiana, Watertown, Wisconsin, Hickory, North Carolina, Sanford, North Carolina, Columbus, Georgia and Columbia,..."/>
LifePoint Health Reports Second Quarter 2016 Results
Ultragenyx Pharmaceutical reported on Thursday the completion of adult patient enrollment under the Phase 3 study of KRN23 for the treatment of adults with X-linked hypophosphatemia, with expected clinical data in 2017.. This Phase 3 study is a randomised, double-blind, placebo-controlled clinical study designed to assess the efficacy and safety of monthly KRN23 in 134 adult XLH patients in the US, EU, Canada, Japan, and Korea who are experiencing..."/>
Ultragenyx concludes X-Linked Hypophosphatemia adult patient admission in Phase 3 Study of KRN23
Chembio Diagnostics, Inc., a leader in point-of-care diagnostic tests for infectious diseases, today announced the upsizing and pricing of its previously announced underwritten public offering of 2,000,000 shares of its common stock at a price to the public of $6.00 per share. In addition, Chembio has granted the underwriters a 30- day option to purchase up to 300,000 additional shares of common stock to cover over-allotments, if any."/>
Chembio Diagnostics, Inc. Announces Upsizing And Pricing Of Public Offering Of Common Stock
Pfizer for undisclosed financial terms. According to the partnership, the oncolytic viruses are viruses engineered to kill cancer cells while sparing healthy cells, which subsequently elicits anti-cancer immune responses. The companies added that WO-12 is a preclinical..."/>
Pfizer partners with Western Oncolytics for oncolytic virus development trials
Teleflex Incorporated on Thursday announced the declaration by its board of directors of a quarterly cash dividend of USD0.34 per share of common stock. The dividend pay out will be made on 15 September 2016 to shareholders of record at the close of business on 15 August 2016.. A provider of medical technologies designed to improve the health and quality of people's lives, Teleflex offers solutions in the fields of vascular and interventional access, surgical, anaesthesia,..."/>
Teleflex’s board declares USD0.34 quarterly dividend
Oculus Innovative Sciences announced on Thursday gross profit of USD1.9m, or 50% of revenue, for the first quarter of fiscal year 2017 ended 30 June 2016.. This is almost flat when compared with a gross profit of USD1.9m, or 51% of revenue when compared to the corresponding period in the prior year. Total revenues of USD3.8m were collected for the first quarter, an increase over total revenues of USD3.7m for the same period in 2015.."/>
Oculus Innovative Sciences discloses Q1 fiiscal 2017 gross profit of USD1.9m
Agile Therapeutics reported on Thursday the election of Seth H. Z. Fischer to its board of directors' compensation and nominating& corporate governance committees with immediate effect. Currently, Fischer is the chief executive officer and a director of Vivus, Inc, a member of the board of directors of BioSig Technologies, Inc as well as an advisor to MedHab. Fischer previously served in positions of increasing responsibility with Johnson& Johnson from..."/>
Agile Therapeutics elects Seth H. Z. Fischer to its board
Spring Bank Pharmaceuticals revealed on Thursday the addition of Todd C. Brady, PhD, MD, AB to its board of directors with immediate effect. Currently, Dr Brady works as the chief executive officer& president of Aldeyra Therapeutics since 2012 as well as a member of its board of directors since 2005.. Dr Brady has recently served as entrepreneur in Residence at Domain Associates, as well as was part of Xanthus Life SciencesInc and Phenome Sciences earlier..."/>
Spring Bank Pharmaceuticals elects Dr Todd C. Brady to board
Reliance Infrastructure Ltd for an enterprise value of Rs.8, 000 crore,..."/>
Deals Buzz: Brookfield front runner to buy out Anil Ambani's road assets [Mint, New Delhi]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology858 Articles
Financials856 Articles
Consumer Discretionary717 Articles
Industrials549 Articles
Health Care545 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at